Recent developments in the third generation inhibitors of Bcr-Abl for overriding T315I mutation

Current Medicinal Chemistry

Volumn 18, Issue 14, 2011, Pages 2146-2157

  Lu, X Y ^a   Cai, Q ^a   Ding, K ^a  

^a INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

Author keywords

Bcr Abl; Chronic myeloid leukemia; DFG in out; Hybrid design; Resistance; T315I mutation; Third generation inhibitors; Tyrosine kinase

Indexed keywords

1 CYCLOPROPYL 3 [3 (5 MORPHOLINOMETHYL 1H BENZIMIDAZOL 2 YL) 1H PYRAZOL 4 YL]UREA; 2 [2 METHOXY 5 (2,4,6 TRIMETHOXYSTYRYLSULFONYLMETHYL)ANILINO]PROPIONIC ACID; ANTINEOPLASTIC AGENT; AP 24163; BCR ABL PROTEIN; DANUSERTIB; DASATINIB; DCC 2036; DSA 3; DSA 7; GNF 2; GNF 5; GNF 6; GNF 7; GNF 8; GNF 9; HG 7 85 01; IMATINIB; NILOTINIB; PONATINIB; PROTEIN INHIBITOR; PYRROLOPYRIDINE A; SGX 393; TG 100598; TG 101113; TG 101223; TOZASERTIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VE 465; [4 [2 CYCLOPENTYL 9 (3 HYDROXYPHENETHYL)PURIN 6 YLAMINO]PHENYL]DIMETHYLPHOSPHINE OXIDE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; CRYSTAL STRUCTURE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME ACTIVITY; HUMAN; HYDROGEN BOND; IC 50; MUTATION; NONHUMAN; QT PROLONGATION; TREATMENT FAILURE;

EID: 79957958724     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711795656135     Document Type: Article

References (58)

1. Nowell, P.C.; Hungerford, D.A. Chromosome studies on normal and leukemic human leukocytes. J. Natl. Cancer Inst., 1960, 25, 85-109.
2. Rowley, J.D. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature, 1973, 243, 290-3.
3. Daley, G.Q.; Van Etten, R.A.; Baltimore, D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science, 1990, 247, 824-30.
4. Renshaw, M.W.; McWhirter, J.R.; Wang, J.Y. The human leukemia oncogene bcr-abl abrogates the anchorage requirement but not the growth factor requirement for proliferation. Mol. Cell. Biol., 1995, 15, 1286-93.
5. Kelliher, M.A.; McLaughlin, J.; Witte, O.N.; Rosenberg, N. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc. Natl. Acad. Sci. U S A, 1990, 87, 6649-53.
6. Schindler, T.; Bornmann, W.; Pellicena, P.; Miller, W.T.; Clarkson, B.; Kuriyan, J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science, 2000, 289, 1938-42.
7. Nagar, B.; Bornmann, W.G.; Pellicena, P.; Schindler, T.; Veach, D.R.; Miller, W.T.; Clarkson, B.; Kuriyan, J. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res., 2002, 62, 4236-43. (Pubitemid 34827278)
8. Shah, N.P.; Tran, C.; Lee, F.Y.; Chen, P.; Norris, D.; Sawyers, C.L. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science, 2004, 305, 399-401. (Pubitemid 38938156)
9. Weisberg, E.; Manley, P.W.; Breitenstein, W.; Bruggen, J.; Cowan-Jacob, S.W.; Ray, A.; Huntly, B.; Fabbro, D.; Fendrich, G.; Hall-Meyers, E.; Kung, A.L.; Mestan, J.; Daley, G.Q.; Callahan, L.; Catley, L.; Cavazza, C.; Azam, M.; Neuberg, D.; Wright, R.D.; Gilliland, D.G.; Griffin, J.D. Characterization of AMN107, a selective inhibitor of native and mutant Bcr- Abl. Cancer Cell, 2005, 7, 129-41. (Pubitemid 40248339)
10. Yokota, A.; Kimura, S.; Masuda, S.; Ashihara, E.; Kuroda, J.; Sato, K.; Kamitsuji, Y.; Kawata, E.; Deguchi, Y.; Urasaki, Y.; Terui, Y.; Ruthardt, M.; Ueda, T.; Hatake, K.; Inui, K.; Maekawa, T. INNO-406, a novel BCRABL/ Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity. Blood, 2007, 109, 306-14. (Pubitemid 46053071)
11. Weisberg, E.; Manley, P.W.; Cowan-Jacob, S.W.; Hochhaus, A.; Griffin, J.D. Second generation inhibitors of BCR-ABL for the treatment of imatinibresistant chronic myeloid leukaemia. Nat. Rev. Cancer., 2007, 7, 345-56. (Pubitemid 46652483)
12. Gorre, M.E.; Mohammed, M.; Ellwood, K.; Hsu, N.; Paquette, R.; Rao, P.N.; Sawyers, C.L. Clinical resistance to STI-571 cancer therapy caused by BCRABL gene mutation or amplification. Science, 2001, 293, 876-80. (Pubitemid 32743979)
13. Druker, B.J.; Sawyers, C.L.; Kantarjian, H.; Resta, D.J.; Reese, S.F.; Ford, J.M.; Capdeville, R.; Talpaz, M. Activity of a specific inhibitor of the BCRABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med., 2001, 344, 1038-42. (Pubitemid 32267973)
14. Corbin, A.S.; Buchdunger, E.; Pascal, F.; Druker, B.J. Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571. J. Biol. Chem., 2002, 277, 32214-9. (Pubitemid 34969036)
15. Pricl, S.; Fermeglia, M.; Ferrone, M.; Tamborini, E. T315I-mutated Bcr-Abl in chronic myeloid leukemia and imatinib: insights from a computational study. Mol. Cancer Ther., 2005, 4, 1167-74. (Pubitemid 41149564)
16. Lee, T.S.; Potts, S.J.; Kantarjian, H.; Cortes, J.; Giles, F.; Albitar, M. Molecular basis explanation for imatinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulations. Cancer, 2008, 112, 1744-53. (Pubitemid 351536834)
17. Tanaka, R.; Kimura, S. Abl tyrosine kinase inhibitors for overriding Bcr- Abl/T315I: from the second to third generation. Expert Rev. Anticancer Ther., 2008, 8, 1387-98.
18. Noronha, G.; Cao, J.; Chow, C.P.; Dneprovskaia, E.; Fine, R.M.; Hood, J.; Kang, X.; Klebansky, B.; Lohse, D.; Mak, C.C.; McPherson, A.; Palanki, M.S.; Pathak, V.P.; Renick, J.; Soll, R.; Zeng, B. Inhibitors of ABL and the ABL-T315I mutation. Curr. Top. Med. Chem., 2008, 8, 905-21. (Pubitemid 351984712)
19. Schenone, S.; Brullo, C.; Botta, M. New opportunities to treat the T315I-Bcr- Abl mutant in chronic myeloid leukaemia: tyrosine kinase inhibitors and molecules that act by alternative mechanisms. Curr. Med. Chem. 2010, 17, 1220-45.
20. Liu, Y.; Gray, N.S. Rational design of inhibitors that bind to inactive kinase conformations. Nat. Chem. Biol. 2006, 2, 358-64. (Pubitemid 43936934)
21. Quintas-Cardama, A.; Cortes, J. Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia. Clin. Cancer. Res. 2008, 14, 4392-9.
22. Zhou, T.; Parillon, L.; Li, F.; Wang, Y.; Keats, J.; Lamore, S.; Xu, Q.; Shakespeare, W.; Dalgarno, D.; Zhu, X. Crystal structure of the T315I mutant of AbI kinase. Chem. Biol. Drug. Des. 2007, 70, 171-81. (Pubitemid 47305404)
23. Arnold, W.D.; Bounaud, P.; Gosberg, A.; Li, Z.; I., M.; Steensma, W.; Wilson, M.E. Pyrrolo-pyridine kinase modulators. WO2006015123 February 9, 2006.
24. TMFragment-based lead discovery and structure-guided design to discovery of small molecule inhibitors of Bcr-Abl tyrosine kinase active against the T315I imatinib-resistant mutant. Blood (ASH Annual Meeting Abstracts), 2005, 106, 698.
25. O'Hare, T.; Eide, C.A.; Tyner, J.W.; Corbin, A.S.; Wong, M.J.; Buchanan, S.; Holme, K.; Jessen, K.A.; Tang, C.; Lewis, H.A.; Romero, R.D.; Burley, S.K.; Deininger, M.W. SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib. Proc. Natl. Acad. Sci. U S A, 2008, 105, 5507-12. (Pubitemid 351753893)
26. Chow, CP.; Cao, J.; Dneprovskaia, E.; Fine, R.; Hanna, E.; Hood, J.D.; Kang, X.; Klebansky, B.; Lohse, D.; Mak, C.C.; McPherson, A.; Noronha, G.; Palanki, M.S.S.; Pathak, V.P.; Renick, J.; Soll, R.; Zeng, B.; Zhu, H. Design and SAR of thiazole-based inhibitors for the ABL-T315I Enzyme. 234th ACS. National Meeting, August 19-23, 2007.
27. Noronha, G.; Barrett, K.; Boccia, A.; Brodhag, T.; Cao, J.; Chow, C.P.; Dneprovskaia, E.; Doukas, J.; Fine, R.; Gong, X.; Gritzen, C.; Gu, H.; Hanna, E.; Hood, J.D.; Hu, S.; Kang, X.; Key, J.; Klebansky, B.; Kousba, A.; Li, G.; Lohse, D.; Mak, C.C.; McPherson, A.; Palanki, M.S.; Pathak, V.P.; Renick, J.; Shi, F.; Soll, R.; Splittgerber, U.; Stoughton, S.; Tang, S.; Yee, S.; Zeng, B.; Zhao, N.; Zhu, H. Discovery of [7-(2,6-dichlorophenyl)-5- methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine- a potent, orally active Src kinase inhibitor with anti-tumor activity in preclinical assays. Bioorg. Med. Chem. Lett., 2007, 17, 602-8. (Pubitemid 46111065)
28. Cao, J.; Fine, R.; Gritzen, C.; Hood, J.; Kang, X.; Klebansky, B.; Lohse, D.; Mak, C.C.; McPherson, A.; Noronha, G.; Palanki, M.S.; Pathak, V.P.; Renick, J.; Soll, R.; Zeng, B.; Zhu, H. The design and preliminary structureactivity relationship studies of benzotriazines as potent inhibitors of Abl and Abl-T315I enzymes. Bioorg. Med. Chem. Lett., 2007, 17, 5812-8. (Pubitemid 47446225)
29. Fancelli, D.; Moll, J.; Varasi, M.; Bravo, R.; Artico, R.; Berta, D.; Bindi, S.; Cameron, A.; Candiani, I.; Cappella, P.; Carpinelli, P.; Croci, W.; Forte, B.; Giorgini, M.L.; Klapwijk, J.; Marsiglio, A.; Pesenti, E.; Rocchetti, M.; Roletto, F.; Severino, D.; Soncini, C.; Storici, P.; Tonani, R.; Zugnoni, P.; Vianello, P. 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile. J. Med. Chem., 2006, 49, 7247-51. (Pubitemid 44886012)
30. Gontarewicz, A.; Balabanov, S.; Keller, G.; Colombo, R.; Graziano, A.; Pesenti, E.; Benten, D.; Bokemeyer, C.; Fiedler, W.; Moll, J.; Brummendorf, T.H. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Blood, 2008, 111, 4355-64.
31. Modugno, M.; Casale, E.; Soncini, C.; Rosettani, P.; Colombo, R.; Lupi, R.; Rusconi, L.; Fancelli, D.; Carpinelli, P.; Cameron, A. D.; Isacchi, A.; Moll, J. Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358. Cancer Res., 2007, 67, 7987-90. (Pubitemid 47395130)
32. Carter, T.A.; Wodicka, L.M.; Shah, N.P.; Velasco, A.M.; Fabian, M.A.; Treiber, D.K.; Milanov, Z. V.; Atteridge, C.E.; Biggs, W.H., 3rd; Edeen, P.T.; Floyd, M.; Ford, J.M.; Grotzfeld, R.M.; Herrgard, S.; Insko, D.E.; Mehta, S.A.; Patel, H.K.; Pao, W.; Sawyers, C.L.; Varmus, H.; Zarrinkar, P.P.; Lockhart, D. J. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc. Natl. Acad. Sci. U S A., 2005, 102, 11011-6. (Pubitemid 41105984)
33. Young, M.A.; Shah, N.P.; Chao, L.H.; Seeliger, M.; Milanov, Z.V.; Biggs, W.H., 3rd; Treiber, D. K.; Patel, H.K.; Zarrinkar, P.P.; Lockhart, D.J.; Sawyers, C.L.; Kuriyan, J. Structure of the kinase domain of an imatinibresistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res., 2006, 66, 1007-14. (Pubitemid 43168337)
34. Giles, F.J.; Cortes, J.; Jones, D.; Bergstrom, D.; Kantarjian, H.; Freedman, S.J. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood., 2007, 109, 500-2. (Pubitemid 46105945)
35. O'Hare, T.; Eide, C.A.; Deininger, M.W. New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check. Expert. Opin. Investig. Drugs, 2008, 17, 865-78. (Pubitemid 351864324)
36. Akahane, D.; Tauchi, T.; Okabe, S.; Nunoda, K.; Ohyashiki, K. Activity of a novel Aurora kinase inhibitor against the T315I mutant form of BCR-ABL: in vitro and in vivo studies. Cancer Sci., 2008, 99, 1251-7. (Pubitemid 351676639)
37. Howard, S.; Berdini, V.; Boulstridge, J.A.; Carr, M.G.; Cross, D.M.; Curry, J.; Devine, L.A.; Early, T.R.; Fazal, L.; Gill, A.L.; Heathcote, M.; Maman, S.; Matthews, J.E.; McMenamin, R.L.; Navarro, E. F.; O'Brien, M.A.; O'Reilly, M.; Rees, D.C.; Reule, M.; Tisi, D.; Williams, G.; Vinkovic, M.; Wyatt, P. G. Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. J. Med. Chem., 2009, 52, 379-88.
38. Tanaka, R.; Squires, M.S.; Kimura, S.; Yokota, A.; Nagao, R.; Yamauchi, T.; Takeuchi, M.; Yao, H.; Reule, M.; Smyth, T.; Lyons, J.F.; Thompson, N.T.; Ashihara, E.; Ottmann, O.G.; Maekawa, T. Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells. Blood, 2010, 116, 2089-95.
39. Zuccotto, F.; Ardini, E.; Casale, E.; Angiolini, M. Through the "gatekeeper door": exploiting the active kinase conformation. J. Med. Chem. 2010, 53, 2681-94.
40. Okram, B.; Nagle, A.; Adrian, F.J.; Lee, C.; Ren, P.; Wang, X.; Sim, T.; Xie, Y.; Wang, X.; Xia, G.; Spraggon, G.; Warmuth, M.; Liu, Y.; Gray, N.S. A general strategy for creating "inactive-conformation" abl inhibitors. Chem. Biol., 2006, 13, 779-86. (Pubitemid 44109805)
41. O'Hare, T.; Pollock, R.; Stoffregen, E.P.; Keats, J.A.; Abdullah, O.M.; Moseson, E.M.; Rivera, V. M.; Tang, H.; Metcalf, C.A., 3rd; Bohacek, R.S.; Wang, Y.; Sundaramoorthi, R.; Shakespeare, W.C.; Dalgarno, D.; Clackson, T.; Sawyer, T.K.; Deininger, M.W.; Druker, B.J. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. Blood, 2004, 104, 2532-9. (Pubitemid 39331857)
42. Azam, M.; Nardi, V.; Shakespeare, W.C.; Metcalf, C.A., 3rd; Bohacek, R.S.; Wang, Y.; Sundaramoorthi, R.; Sliz, P.; Veach, D.R.; Bornmann, W.G.; Clarkson, B.; Dalgarno, D.C.; Sawyer, T. K.; Daley, G.Q. Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance. Proc. Natl. Acad. Sci. U S A., 2006, 103, 9244-9. (Pubitemid 43902563)
43. Huang, W.S.; Zhu, X.; Wang, Y.; Azam, M.; Wen, D.; Sundaramoorthi, R.; Thomas, R.M.; Liu, S.; Banda, G.; Lentini, S.P.; Das, S.; Xu, Q.; Keats, J.; Wang, F.; Wardwell, S.; Ning, Y.; Snodgrass, J.T.; Broudy, M.I.; Russian, K.; Daley, G.Q.; Iuliucci, J.; Dalgarno, D.C.; Clackson, T.; Sawyer, T.K.; Shakespeare, W.C. 9-(Arenethenyl)purines as dual Src/Abl kinase inhibitors targeting the inactive conformation: design, synthesis, and biological evaluation. J. Med. Chem., 2009, 52, 4743-56.
44. Azam, M.; Powers, J.T.; Einhorn, W.; Huang, W.S.; Shakespeare, W.C.; Zhu, X.; Dalgarno, D.; Clackson, T.; Sawyer, T.K.; Daley, G.Q. AP24163 inhibits the gatekeeper mutant of BCR-ABL and suppresses in vitro resistance. Chem. Biol. Drug. Des., 2010, 75, 223-7.
45. Huang, W.S.; Metcalf, C.A.; Sundaramoorthi, R.; Wang, Y.; Zou, D.; Thomas, R.M.; Zhu, X.; Cai, L.; Wen, D.; Liu, S.; Romero, J.; Qi, J.; Chen, I.; Banda, G.; Lentini, S.P.; Das, S.; Xu, Q.; Keats, J.; Wang, F.; Wardwell, S.; Ning, Y.; Snodgrass, J.T.; Broudy, M.I.; Russian, K.; Zhou, T.; Commodore, L.; Narasimhan, N.I.; Mohemmad, Q.K.; Iuliucci, J.; Rivera, V.M.; Dalgarno, D.C.; Sawyer, T.K.; Clackson, T.; Shakespeare, W.C. Discovery of 3-[2-(imidazo[1,2-b] pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl] -3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster regionabelson (BCR-ABL) kinase including the T315I gatekeeper mutant. J. Med. Chem., 2010, 53, 4701-19.
46. O'Hare, T.; Shakespeare, W.C.; Zhu, X.; Eide, C.A.; Rivera, V.M.; Wang, F.; Adrian, L.T.; Zhou, T.; Huang, W.S.; Xu, Q.; Metcalf, C.A., 3rd; Tyner, J.W.; Loriaux, M.M.; Corbin, A.S.; Wardwell, S.; Ning, Y.; Keats, J.A.; Wang, Y.; Sundaramoorthi, R.; Thomas, M.; Zhou, D.; Snodgrass, J.; Commodore, L.; Sawyer, T.K.; Dalgarno, D.C.; Deininger, M.W.; Druker, B.J.; Clackson, T. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell., 2009, 16, 401-12.
47. http://clinicaltrials.gov/ct2/show/NCT01207440.
48. Deng, X.; Lim, S.M.; Zhang, J.; Gray, N.S. Broad spectrum alkynyl inhibitors of T315I Bcr-Abl. Bioorg. Med. Chem. Lett., 2010, 20, 4196-200.
49. Choi, H. G.; Ren, P.; Adrian, F.; Sun, F.; Lee, H. S.; Wang, X.; Ding, Q.; Zhang, G.; Xie, Y.; Zhang, J.; Liu, Y.; Tuntland, T.; Warmuth, M.; Manley, P. W.; Mestan, J.; Gray, N. S.; Sim, T. A type-II kinase inhibitor capable of inhibiting the T315I "gatekeeper" mutant of Bcr-Abl. J. Med. Chem., 2010, 53, 5439-48.
50. Azam, M.; Seeliger, M.A.; Gray, N.S.; Kuriyan, J.; Daley, G.Q. Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat. Struct. Mol. Biol., 2008, 15, 1109-18.
51. Weisberg, E.; Choi, H.G.; Ray, A.; Barrett, R.; Zhang, J.; Sim, T.; Zhou, W.; Seeliger, M.; Cameron, M.; Azam, M.; Fletcher, J.A.; Debiec-Rychter, M.; Mayeda, M.; Moreno, D.; Kung, A.L.; Janne, P.A.; Khosravi-Far, R.; Melo, J.V.; Manley, P.W.; Adamia, S.; Wu, C.; Gray, N.; Griffin, J.D. Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants. Blood, 2010, 115, 4206-16.
52. Seeliger, M.A.; Ranjitkar, P.; Kasap, C.; Shan, Y.; Shaw, D.E.; Shah, N.P.; Kuriyan, J.; Maly, D.J. Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations. Cancer Res., 2009, 69, 2384-92.
53. Cardama, A.Q. Experimental non-ATP-competitive therapies for chronic myelogenous leukemia. Leukemia, 2008, 22, 932-940.
54. Gumireddy, K.; Baker, S.J.; Cosenza, S.C.; John, P.; Kang, A.D.; Robell, K.A.; Reddy, M.V.; Reddy, E.P. A non-ATP-competitive inhibitor of BCRABL overrides imatinib resistance. Proc. Natl. Acad. Sci. U S A., 2005, 102, 1992-7. (Pubitemid 40262000)
55. Zhang, J.; Adrian, F.J.; Jahnke, W.; Cowan-Jacob, S.W.; Li, A.G.; Iacob, R.E.; Sim, T.; Powers, J.; Dierks, C.; Sun, F.; Guo, G.R.; Ding, Q.; Okram, B.; Choi, Y.; Wojciechowski, A.; Deng, X.; Liu, G.; Fendrich, G.; Strauss, A.; Vajpai, N.; Grzesiek, S.; Tuntland, T.; Liu, Y.; Bursulaya, B.; Azam, M.; Manley, P.W.; Engen, J.R.; Daley, G.Q.; Warmuth, M.; Gray, N.S. Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature, 2010, 463, 501-6.
56. Van Etten, R.A.; Chan, W.W.; Zaleskas, V.M.; Evangelista, P.; Lazarides, K.; Peng, C.; Li, S.; Wise, S.C.; Petillo, P.; Flynn, D.L. DCC-2036: A novel switch pocket inhibitor of ABL tyrosine kinase with therapeutic efficacy against BCR-ABL T315I in vitro and in a CML mouse model. Blood, (ASH Annual Meeting Abstracts), 2007, 110, 463.
57. Adrian, F.J.; Ding, Q.; Sim, T.; Velentza, A.; Sloan, C.; Liu, Y.; Zhang, G.; Hur, W.; Ding, S.; Manley, P.; Mestan, J.; Fabbro, D.; Gray, N. S. Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat. Chem. Biol., 2006, 2, 95-102.
58. Fabbro, D.; Manley, P.W.; Jahnke, W.; Liebetanz, J.; Szyttenholm, A.; Fendrich, G.; Strauss, A.; Zhang, J.; Gray, N.S.; Adrian, F.; Warmuth, M.; Pelle, X.; Grotzfeld, R.; Berst, F.; Marzinzik, A.; Cowan-Jacob, S.W.; Furet, P.; Mestan, J. Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site. Biochim. Biophys. Acta., 2010, 1804, 454-62.